MYBL2 and neoplasm: When the prognostic implications of the genetic aberrations were separately examined in HR+ and HR- tumors, a combination of mutations and gain of PIK3CA, a combined aberration of the PI3K pathway genes, and gain of FOXA1, CDH3, BIRC5, MYBL2, and AIB1 indicated worse RFS rates only in patients with a HR+ tumor (Table 4).